
    
      A five week randomised-withdrawal phase (Part B) for a subset of subjects who took part in a
      38 week, multicentre, open label (Part A) follow-on study to evaluate, the maintenance of
      effect of, the development of tolerance through exposure to, and safety of, SativexÂ® in the
      treatment of subjects with neuropathic pain. Subjects returned to the centre for an end of
      treatment visit at week 38 of Part A (Visit 5, Day 266), followed by Visits 5b (week 39), 5c
      (week 43) and an end of study visit took place 28 days after Visit 5c or withdrawal from the
      study.
    
  